Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ScRNA-Seq analysis of a glioblastoma patient sample after Vortioxetine or DMSO treatment

ABSTRACT: Vortioxetine is the neuroactive drug with the highest ex vivo anti-glioblastoma efficacy across patients measured in our study. We used single-cell RNA sequencing (scRNA-seq) to analyze the transcriptomic response to Vortioxetine treatment.

ORGANISM(S): Homo sapiens

PROVIDER: GSE214967 | GEO | 2024/07/29

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

scRNA-Seq analysis of adult glioblastoma patient samples

Project description:Glioblastoma is the most common type of malignant brain tumor among adults. We used single-cell RNA sequencing (scRNA-seq) to analyze the diversity of glioblastoma cells.

2024-07-25 | GSE214966 | GEO

scRNA-seq of brain glioblastoma sample

Project description:scRNA-seq of brain glioblastoma sample

| PRJNA1141154 | ENA

scRNA-Seq analysis of a glioblastoma patient sample after Vortioxetine or DMSO treatment

Project description:scRNA-Seq analysis of a glioblastoma patient sample after Vortioxetine or DMSO treatment

| PRJNA887805 | ENA

High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity

Project description:Glioblastoma, the most aggressive primary brain cancer, has dismal prognosis, yet systemic treatment is limited to DNA-alkylating chemotherapies. New therapeutic strategies may emerge from exploring neurodevelopmental and neurophysiological vulnerabilities of glioblastoma. To this end, we here systematically screen repurposable neuroactive drugs in glioblastoma patient surgery material using a clinically concordant and single-cell resolved platform. Profiling >2,500 ex vivo drug responses across 27 patients and 132 drugs identified class-diverse neuroactive drugs with potent anti-glioblastoma efficacy that were validated across model systems. Interpretable molecular machine learning of drug-target networks revealed neuroactive convergence on AP-1/BTG-driven glioblastoma suppression, enabling expanded in silico screening of >1 million compounds with high patient validation accuracy. Deep multi-modal profiling confirmed Ca2+-driven AP-1/BTG-pathway induction as a neuro-oncological glioblastoma vulnerability, epitomized by the antidepressant Vortioxetine synergizing with current standard-of-care chemotherapies in vivo. These findings establish an actionable framework for glioblastoma treatment rooted in its neural etiology.

| MSV000090357 | MassIVE

scRNA-seq of brain glioblastoma sample

Project description:Proneural-mesenchymal transition (PMT) is a phenotypic alteration and contributes to therapeutic resistance and recurrence of glioblastoma (GBM). Macrophages, as a main infiltrating component of tumor immune microenvironment (TIM), can regulate the biological processes of PMT. However, the mechanisms driving this process remain largely unknown. Here, We performed single-cell RNA sequencing (scRNA-seq) (3V3) and Spatial transcriptomics RNA sequencing(stRNA-seq)(1V1) from tumor core and matching tumor periphery samples to discripe the overall landscape of tumor and nontumor cells in gliomas.

2024-12-11 | GSE273274 | GEO

scRNA-Seq analysis of adult glioblastoma patient samples

Project description:scRNA-Seq analysis of adult glioblastoma patient samples

| PRJNA887804 | ENA

scRNA-seq of pediatric glioblastoma patient-derived xenografts

Project description:scRNA-seq of pediatric glioblastoma patient-derived xenografts

| PRJNA482625 | ENA

PDGF-driven glioblastoma mouse model scRNA-Seq

Project description:Generate scRNA-Seq profiles for PDGF-driven glioblastoma mouse model.

2018-02-23 | GSE95157 | GEO

stRNA-seq of brain glioblastoma sample

2024-12-11 | GSE273275 | GEO

Gene expression of patient derived xenograft glioblastoma treated with DMSO control or Panobinostat.

Project description:Panobinostat is a non-selective histone deactylase inhibitor which has been approved by FDA for treatment of mutiple myeloma. Whether and how the drug works on glioblastoma remains unclear. Here we treated mice implanted with patient derived xenograft glioblastoma G43 with DMSO or Panobinostat and harvest the tumors for microarray analysis for gene expression results.

2019-01-09 | GSE108957 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data